Skip to main content
. 2021 Dec 8;191(6):2467–2474. doi: 10.1007/s11845-021-02689-x

Table 2.

Treatments

BRAF-Mutated (n = 20) BRAF-Wild type (n = 36) p
Chemotherapy
 Folfox 16 (80%) 32 (89%) p = 0.61
 Folfiri 10 (50%) 19 (53%) p = 0.94
 Cetuximab 19 (95%) 30 (83%) p = 0.40
 5FU 1 (5%) 3 (8%) p = 0.94
 Bevacizumab 8 (40%) 20 (56%) p = 0.40
Surgery
 Primary resection 13 30 p = 0.22